Health for Small businesses Grants

This Notice of Funding Opportunity (NOFO) invites applications from eligible small businesses to develop solutions for commercialization that can be used to enable regional clinician-to-clinician genomic medicine eConsult services. Specifically, we seek products, such as technologies or services, that will allow for the development and sustainment of eConsult services. Eligible United States small business concerns (SBCs) may submit Small Business Technology Transfer (STTR) Phase I, and Fast-Track grant applications. Small business applicants interested in submitting a Small Business Innovation Research (SBIR) grant application should submit to the related funding opportunity, PAR-24-106. SBIR and STTR are phased programs. The main objective in SBIR and STTR Phase I is to establish the technical merit and feasibility of the proposed research and development efforts. An SBIR and STTR Phase II continues the R&D efforts to advance the technology toward ultimate commercialization. At the conclusion of an SBIR/STTR Phase II, it is expected that the small business will fully commercialize their product or technology using non-SBIR/STTR funds (either federal or non-federal). Small businesses that are eligible to submit Phase II applications for projects that were supported with a Phase I SBIR or STTR award are expected to submit the regular Phase II application as a "Renewal" application based on the awarded Phase I SBIR or STTR project. Only one Phase II application may be awarded for a specific project supported by a Phase I award.

This Notice of Funding Opportunity (NOFO) invites applications from eligible small businesses to develop solutions for commercialization that can be used to enable regional clinician-to-clinician genomic medicine eConsult services. Specifically, we seek products, such as technologies or services, that will allow for the development and sustainment of eConsult services. Eligible United States small business concerns (SBCs) may submit Small Business Innovation Research (SBIR) Phase I, Direct to Phase II, and Fast-Track grant applications. Small business applicants interested in submitting a Small Business Technology Transfer (STTR) grant application should submit to the related funding opportunity, PAR-24-107. SBIR and STTR are phased programs. The main objective in SBIR and STTR Phase I is to establish the technical merit and feasibility of the proposed research and development efforts. An SBIR and STTR Phase II continues the R&D efforts to advance the technology toward ultimate commercialization. At the conclusion of an SBIR/STTR Phase II, it is expected that the small business will fully commercialize their product or technology using non-SBIR/STTR funds (either federal or non-federal). Small businesses that are eligible to submit Phase II applications for projects that were supported with a Phase I SBIR or STTR award are expected to submit the regular Phase II application as a "Renewal" application based on the awarded Phase I SBIR or STTR project. Only one Phase II application may be awarded for a specific project supported by a Phase I award. NIH Fast-Track: An NIH SBIR Fast-Track incorporates a submission and review process in which both Phase I and Phase II applications are submitted and reviewed together as one application to reduce or eliminate the funding gap between phases. NIH Direct to Phase II: For small businesses that have already demonstrated scientific and technical merit and feasibility but have not received a Phase I SBIR or STTR for that project, NIH can issue a Direct to Phase II award. The NIH will accept Direct to Phase II applications regardless of the funding source for the proof of principle work on which the proposed Phase II research is based. Direct to Phase II awards should be submitted as “New” applications and not continuations ("Renewal") of Phase I SBIR or STTR projects.

This Notice of Funding Opportunity (NOFO) invites applications for the continued support and advancement of the Mutant Mouse Resource and Research Centers (MMRRC). The MMRRC consortium is expected to facilitate research by identifying, acquiring, evaluating, characterizing, cryopreserving, and distributing mutant mouse strains to qualified biomedical investigators. A regional network of four MMRRCs and an Informatics, Coordination and Service Center (ICSC) collectively serve the needs of the biomedical research community for transgenic, knockout and other genetically-engineered mutant mice and related biomaterials. MMRRC strains are held to the highest standards to optimize reproducibility of studies and assure scientific rigor and transparency; all submitted strains are thoroughly reviewed and documented and include additional quality control measures. The Program Director/Principal Investigator (PD/PI) of each MMRRC in addition to the major resource activities is required to develop a small high risk, high return, research pilot project that complements the goals and needs of the MMRRC consortium. ORIP intends to fund up to four awards, but the overall number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications Award Budget Requested Direct Costs must reflect actual needs of the project. For Renewal (a.k.a. Type 2) applications, no more than a 5 percent (direct cost) increase from the last non-competing year will be accepted. ORIP intends to fund up to four awards, but the overall number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications

This funding opportunity supports existing Centers for AIDS Research in expanding training and research initiatives focused on HIV and health disparities, particularly for underrepresented groups and early-career investigators.

This funding opportunity supports small businesses in conducting early-stage clinical trials for innovative treatments of vision-related disorders, ensuring safety and collaboration with the National Eye Institute.

This funding opportunity provides financial support to small businesses in the U.S. for conducting early-phase clinical trials of innovative treatments for neurological disorders.

This funding opportunity provides financial support for small businesses to conduct exploratory clinical trials focused on neurological disorders, including the development of drugs, devices, and therapies.

This funding opportunity supports U.S.-based small businesses in developing automated and miniaturized systems that replicate human tissue functions for improved drug testing and biomedical research.

This funding opportunity supports U.S. small businesses in developing automated and miniaturized tissue chip systems to improve biomedical research and drug development.

This funding opportunity provides financial support to institutions with active Clinical and Translational Science Awards to develop innovative programs that address critical challenges in clinical research and improve the efficiency of translating scientific discoveries into practical applications.

This funding opportunity is designed for U.S.-based small businesses to create engaging digital educational tools that teach pre-college students and teachers about biomedical sciences through interactive learning.

This funding opportunity provides support to existing National Primate Research Centers in the U.S. to enhance biomedical research through the management of nonhuman primate colonies and related scientific resources.

The purpose of this Funding Opportunity Announcement (FOA) is to facilitate the transition of previously funded SBIR and STTR Phase II and Phase IIB projects in pain management to the commercialization stage by providing additional assistance for private partnering activities through the Commercialization Readiness Pilot (CRP) program. Specifically, this FOA supports the addition of entrepreneurial expertise into small business leadership teams along with supporting partnering activities to aid in commercialization through private third-party funding or partnership with industry.

This funding opportunity supports institutions that have successfully completed an initial phase of a biomedical research program, enabling them to further develop research capabilities and enhance the careers of early-stage investigators.

This funding opportunity provides financial support to small businesses collaborating with academic or non-profit labs to develop and commercialize innovative technologies and treatments for arthritis, musculoskeletal, and skin diseases.

This funding opportunity provides financial support for small businesses to develop innovative products and services aimed at preventing, diagnosing, and treating Alzheimer's disease and related dementias, ultimately improving care for affected individuals and their families.

This funding opportunity provides financial support for small businesses and researchers to develop innovative products and services aimed at preventing, diagnosing, and treating Alzheimer's disease and related dementias, ultimately improving care for affected individuals and their families.

The "Limited Competition: NIGMS Mature Synchrotron Resources for Structural Biology" grant aims to fund well-established structural biology resources at synchrotron facilities, with the goal of maintaining or upgrading them to current best practices, promoting their availability to the biomedical research community, and providing user training and support.

This funding opportunity provides financial support to small businesses developing new medications for treating alcohol use disorder and related organ damage, helping them advance their research towards FDA approval.

This funding opportunity provides financial support to small businesses developing new medications for treating alcohol use disorder and related organ damage, with a focus on advancing these therapies toward FDA approval.